Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00379340 · OUTCOME

Event Free Survival Probability

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor · Source last updated 2026-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Probability of EFS at 4 years
Interval / dispersion
95% Confidence Interval
Time frame
At 4 years

What was measured

Probability of no relapse, secondary malignancy, or death after 4 year in the study

Analysis population: All eligible patients were included in this analysis.

Groups in this outcome

Stage III/IV With LOH 1p and 16q Treated With Regimen M

Stage III/IV with LOH 1p and 16q treated with Regimen M doxorubicin hydrochloride: Given IV liposomal vincristine sulfate: Given IV conventional surgery 3-dimensional conformal radiation therapy dactinomycin: Given IV cyclophosphamide: Given IV etoposide: Given IV

Stage IV With Non-lung Disease Treated With Regimen M

Stage IV with non-lung disease treated with Regimen M doxorubicin hydrochloride: Given IV liposomal vincristine sulfate: Given IV conventional surgery dactinomycin: Given IV cyclophosphamide: Given IV etoposide: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Stage III/IV With LOH 1p and 16q Treated With Regimen M52
Stage IV With Non-lung Disease Treated With Regimen M50

Reported measurements

Source class 1
Values in Probability of EFS at 4 years · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Stage III/IV With LOH 1p and 16q Treated With Regimen M0.90Not reported0.801Not reported
Stage IV With Non-lung Disease Treated With Regimen M0.73Not reported0.590.88Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.80
        upper Limit
        1
        value
        0.90
      2. group Id
        OG001
        lower Limit
        0.59
        upper Limit
        0.88
        value
        0.73
denoms
  1. counts
    1. group Id
      OG000
      value
      52
    2. group Id
      OG001
      value
      50
    units
    Participants
description
Probability of no relapse, secondary malignancy, or death after 4 year in the study
dispersion Type
95% Confidence Interval
groups
  1. description
    Stage III/IV with LOH 1p and 16q treated with Regimen M doxorubicin hydrochloride: Given IV liposomal vincristine sulfate: Given IV conventional surgery 3-dimensional conformal radiation therapy dactinomycin: Given IV cyclophosphamide: Given IV etoposide: Given IV
    id
    OG000
    title
    Stage III/IV With LOH 1p and 16q Treated With Regimen M
  2. description
    Stage IV with non-lung disease treated with Regimen M doxorubicin hydrochloride: Given IV liposomal vincristine sulfate: Given IV conventional surgery dactinomycin: Given IV cyclophosphamide: Given IV etoposide: Given IV
    id
    OG001
    title
    Stage IV With Non-lung Disease Treated With Regimen M
param Type
NUMBER
population Description
All eligible patients were included in this analysis.
reporting Status
POSTED
time Frame
At 4 years
title
Event Free Survival Probability
type
PRIMARY
unit Of Measure
Probability of EFS at 4 years

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice